U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DKT NO.
T103 F1016.1SERIAL NO.
09/526,403SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Sanberg, *et al.*FILING DATE
03/15/2000GROUP
1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL.	TRANSLATION	
							YES	NO
<i>r</i>	F1	EP 0 537 993 A1	21 April 1993	EP				

OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)


<i>r</i>	D1	Hayashi, E., <i>et al.</i> , "Comparative studies on anti-nicotinic action of hexamethonium, mecamlamine and adenosine in the guinea pig isolated ileum," <i>Japan J. Pharmacol.</i> 27: 659-665 (1997).
<i>f</i>	D2	Sanberg, P.R., <i>et al.</i> , "Nicotine for the Treatment of Tourette's Syndrome," <i>Pharmacol. Ther.</i> 74(1): 21-25 (1997).
<i>f</i>	D3	Suchocki, J.A., <i>et al.</i> , "Synthesis of 2-exo- and 2-end-mecamlamine analogs. Structure-activity relationships for nicotinic antagonism in the central nervous system," <i>Journal of Medicinal Chemistry</i> , 34: 1003-1010 (1991).
<i>r</i>	D4	European Patent Application No. 98 93 9328.5, Supplementary European Search Report issued December 3, 2003.

EXAMINER

DATE CONSIDERED

12/10/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 F1016.1		SERIAL NO. 09/526,403		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Paul R. Sanberg, <i>et al.</i>				
				FILING DATE 03/15/2000		GROUP		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.	
✓	P1	2,831,027	4/1958	Pfister, III, <i>et al.</i>	260	563		
	P2	2,894,987	7/1959	Gustav, <i>et al.</i>	260	563		
	P3	3,148,118	9/1964	Thesing, <i>et al.</i>	167	65		
	P4	3,164,601	1/1965	Thesing, <i>et al.</i>	260	294.7		
	P5	4,837,218	6/1989	Olney	514	646		
	P6	4,891,380	1/1990	Williams, <i>et al.</i>	514	353		
	P7	5,554,610	9/1996	Williams, <i>et al.</i>	514	223.2		
	P8	5,574,052	11/1996	Rose, <i>et al.</i>	514	343		
	P9	5,583,140	12/1996	Bencherif, <i>et al.</i>	514	299		
	P10	5,691,365	11/1997	Crooks, <i>et al.</i>	514	343		
	P11	5,859,004	1/1999	Olesen	514	214		
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL.	TRANSLATION	
							YES	NO
EXAMINER					DATE CONSIDERED			
[Signature]					12/10/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DKT NO.
T103 F1016.1

SERIAL NO.
09/526,403

APPLICANT
Paul R. Sanberg, et al.

FILING DATE
03/15/2000

GROUP

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)


- | | |
|-----|---|
| D1 | Ballivet, et al., "Nicotine Acetylcholine . . . elegans," JMB., 2296, pp. 261-269 (1996) |
| D2 | Banerjee, et al., "[3H]Mecamylamine Binding to Rat Brain Membranes," <i>Biochemical Pharmacology</i> , Vol. 40, No. 9, pp. 2105-2110 (1990) |
| D3 | Bianchi, C. and L. Tomasi, "Central nervous system and autonomic nervous system effects of amantadine and of some standard anti-Parkinson drugs," <i>Pharmacology</i> , 10(4): 226-237 (1973). |
| D4 | Bruun, R.D. and C.L. Budman, "Risperidone as a treatment for Tourette's syndrome," <i>J.Clin. Psychiatry</i> , 57(1): 29-31 (1996). |
| D5 | Emerich, et al., "Nicotine . . . Locomotor Hypoactivity," <i>Pharm. Biochem. & Behav.</i> , Vol. 38, pp. 875-880 (1991) |
| D6 | Emerich, et al., "Nicotine . . . of Haloperidol, Psychopharm. Bulletin., Vol. 27(3): 385-390 (1991). |
| D7 | Erdmann, R., "Nicotine in neuropsychiatric movement disorders," <i>Fortschr Neurol Psychiatr.</i> , 64(9): 362-366 (1996). |
| D8 | Freund, R.K., et al., "Nicotine effects in mouse hippocampus are blocked by mecamylamine, but not other nicotinic antagonists," <i>Brain Res.</i> , 511(2): 187-191 (1990). |
| D9 | Ghaemi, S.N., et al., "Acute treatment of bipolar disorder with adjunctive risperidone in outpatients," <i>Can. J. Psychiatry</i> , 42(2): 196-199 (1997). |
| D10 | Green, M.F., et al., "Does Risperidone Improve Verbal Working Memory in Treatment-Resistant Schizophrenia?" <i>American Journal of Psychiatry</i> , 154(6): 799-804 (1997). |
| D11 | Hsu, W., "Toxicity and Drug Interactions of Levamisole," <i>HAVMA</i> , Vol. 176, No. 10, pp. 1166-1169 (May 1980) |
| D12 | Ivanová, S. and A. J. Greenshaw, "Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron," <i>Psychopharmacology</i> , 134(2): 187-192 (1997). |
| D13 | Jankovic, J. and H. Rohaidy, "Motor, behavior and pharmacologic findings in Tourette's Syndrome," <i>Can. J. Neurol. Sci.</i> , 14(3 Suppl.): 541-546 (1987). |
| D14 | Jolles, J., et al., "Cognitive Impairment in Elderly People," <i>Drugs & Aging</i> , 7(6): 459-479 (1995). |
| D15 | <i>The Lancet</i> , "Nicotine Gum & Haloperidol in Tourette's Syndrome," p. 592 (Mar. 12, 1998) |
| D16 | <i>The Lancet</i> , "Transdermal nicotine patch . . . in Tourette's Syndrome," Vol. 342, P. 182 (Jul. 17, 1993) |
| D17 | Levin, E. D. and D. Torry, "Acute and chronic nicotine effects on working memory in aged rats," <i>Psychopharmacology</i> , 123: 88-97 (1996). |
| D18 | Lindström, E., et al., "Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia," <i>Clin. Ther.</i> 17(3): 402-412 (1995). |
| D19 | Lombroso, P.J., et al., "Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report," <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , 34(9): 1147-1152 (1995). |
| D20 | Lombroso, P.J., et al., "Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report," <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , 35(3): 394 (1996). |
| D21 | McConville, et al., "The Effects . . . in Tourette's Disorder," <i>Biol. Psychiatry</i> , Vol. 31(8): 832-840 (1992) |
| D22 | McConville, et al., "Nicotine . . . in Tourette's Syndrome," <i>Amer. J. Psychiatry</i> , 148(6): 793-794 (Jun. 1991) |
| D23 | <i>Pharmacol Ther.</i> , "Nicotine for the Treatment of Tourette's Syndrome," Vol. 74, No. 1, pp. 21-25 (1997) |
| D24 | <i>Psychopharmacologia</i> (Berl.), "Nicotine-Like . . . after . . . Mecamylamine in . . . rats," 46, pp. 119-121 (1976) |

EXAMINER

DATE CONSIDERED

12/10/00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 F1016.1	SERIAL NO. 09/526,403
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
		APPLICANT Paul R. Sanberg, et al.		FILING DATE 03/15/2000	
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)					
D25	Rupniak, et al. "Antinociceptive and Toxic Effect . . . Attributable to Nicotinic Agonist Activity," <i>Brit. J. Pharmacol.</i> , 113(4): 1487-1493 (1994)				
D26	Sallee, F.R., et al., "Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder," <i>Acta. I Psychiatr. Scand.</i> , 90(1): 4-9 (1994).				
D27	Sallee, F.R., et al., "Pharmacokinetics of pimozide in adults and children with Tourette's syndrome," <i>J. Clin. Pharmacol.</i> , 27(10): 776-781 (1987)				
D28	Sallee, F.R., et al., "Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder," <i>Am. J. Psychiatry</i> , 154(8): 1057-1062 (1997).				
D29	Sanberg, et al., "Nicotine as a Therapeutic Adjunct for Tourette's Syndrome," pp. 35-41 (1997)				
D30	Sanberg, et al., "Nicotine . . . with Tourette's Syndrome," <i>Biomed & Pharmacother.</i> , 43, pp. 19-23 (1989)				
D31	Sanberg, et al., "Nicotine . . . Striatal Mechanisms," <i>Pharmacol. Biochem & Behavior</i> , Vol. 46: 303-307 (1993)				
D32	Sano Corporation website (1997)				
D33	Sawada, S., et al., "Augmenting action of nicotine on population spikes in the dentate gyrus of the guinea pig," <i>Neurosci Res.</i> , 20(4): 317-322 (1994).				
D34	Schonenberger, et al., "Preparation of Optically Active . . .," <i>Helvetica Chimica Acta</i> , Vol. 69, pp. 283-287 (1986).				
D35	Seumaru, et al., "Characteristics of tail-tremor induced by nicotine in rats," <i>Naonyn-Schmledeberg's Arch Pharmacol</i> , 350:153-157 (1994).				
D36	Shapiro, E., et al., "Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome," <i>Arch. Gen. Psychiatry</i> , 46(8): 722-730 (1989).				
D37	Shieh, et al., "Sexual Differences in the Diurnal Changes . . . of Neuron Activity in Rat: Role of Cholinergic Control," <i>Biology of Reproduction</i> , Vol. 54, pp. 987-992 (1996)				
D38	Shytle, et al., "Nicotine, Tobacco and Addiction," <i>Int'l Weekly Journal of Science</i> , Vol. 384, PP. 18-19 (1997)				
D39	Shytle, et al., "Researchers Exploring . . . TS Treatment," <i>Tourette Syn. Assoc.</i> , 25(1): 1, 3, 7 (1997)				
D40	Shytle, et al., "Transdermal Nicotine for Tourette's Syndrome," <i>Drug Development Research</i> , Vol. 38, pp. 290-298 (1996)				
D41	Silver, et al., "Case Study . . . In Tourette's Syndrome," <i>J. Amer. Child & Adolesc. Psych.</i> , Vol. 35(12), pp. 1631-1636 (1996)				
D42	Stone, et al., "Chemistry and Structure-Activity Relationship of Mecamylamine and Derivatives," <i>Journal of Medicine & Pharm. Chemistry</i> , Vol., 5(4), pp. 665-690 (1962)				
D43	The Merk Index, "5654. Mecamylamine," p. 905 (1989)				
EXAMINER		DATE CONSIDERED			
		12/10/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					